Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414466 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL31097912 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL2904552 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL32681153 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL7684 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL11542843 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL18124365 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL19283519 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444696 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444694 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | claimed |
| US-20240376102-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | NATCO PHARMA LIMITED (IN) | 2024-11-14 | — | — | US | claimed |
| WO-2024130425-A1 | METHODS OF MAKING 2-AMINO-L-(3-HYDROXY-2,6-DIMETHYLPHENYL)-5,6- DIMETHYL-LH-PYRROLO-[2,3-B]PYRIDINE-3-CARBOXAMIDE, A MYTL INHIBITOR | REPARE THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| WO-2023042224-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | NATCO PHARMA LIMITED (IN) | 2023-03-23 | — | — | WO | claimed |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | RADIUS HEALTH, INC. | 2022-05-26 | — | — | US | claimed |
| EP-3924328-A1 | PROCESSES AND COMPOUNDS | Radius Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| US-20100331544-A1 | METHOD FOR PRODUCING (1R,5S) ANHYDROECGONINE ESTER SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-30 | — | — | US | claimed |
| CN-101130520-B | Novel method for splitting and producing natural (-)-huperzine and non- natural (+)-huperzine by racemate of diastereoisomer salt | SHANGHAI INST MATERIA MEDICA | 2010-05-12 | — | — | CN | claimed |
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| CN-101258151-A | Process for the synthesis of stereoisomeric compounds useful in the treatment of gastrointestinal and central nervous system disorders and intermediates | ARYX THERAPEUTICS INC (US) | 2008-09-03 | — | — | CN | claimed |
| EP-1919909-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | Aryx Therapeutics, Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| CN-101130520-A | Novel method for splitting and producing natural (-)-huperzine and non- natural (+)-huperzine by racemate of diastereoisomer salt | SHANGHAI INST MATERIA MEDICA (CN) | 2008-02-27 | — | — | CN | claimed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007028073-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | CES1 3892/4885SRC 644/4885CES2 3738/4885 |
| US-20100331544-A1 | METHOD FOR PRODUCING (1R,5S) ANHYDROECGONINE ESTER SALTS | GNE, ABHD5, GALE | CES1 241/4885SRC 3552/4885CES2 523/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | CES1 901/4885SRC 2768/4885CES2 1565/4885 |
| US-20240376102-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | JAK1, JAK2, FLT3 | CES1 3169/4885SRC 300/4885CES2 4771/4885 |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | CES1 4624/4885SRC 992/4885CES2 4884/4885 |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, CYP19A1 | CES1 191/4885SRC 1526/4885CES2 545/4885 |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | CES1 4624/4885SRC 992/4885CES2 4884/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | CES1 692/4885SRC 4395/4885CES2 787/4885 |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | CES1 692/4885SRC 4395/4885CES2 787/4885 |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, BRAF | CES1 2590/4885SRC 236/4885CES2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.